Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

ARS Pharmaceuticals Inc. - news published 404 - readings 2.486

BACK

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

21.03.2025

ARS Pharmaceuticals Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 81-1489190 (State or other jurisdiction of incorpo ...

20.03.2025

ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Form 8-K)

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expan ...

20.03.2025

ARS Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Management's Discussion and Analysis o f Financial Condition and Results of Operations. You should read the following discussion and analysis together with our financial statements and related notes included in "Item 8. Financial Statements and Supplementary Data" in this Annual Report. The following discussion contains forward-looking statements that involve risks a ...

20.03.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

07.03.2025

ARS Pharmaceuticals Inc.

Material Event (Form 8-K)

Item 8.01 Other Events. FDA Approval of neffy ® 1 mg (epinephrine nasal spray) On March 5, 2025, ARS Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") approved neffy 1 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including anaphylaxis, in children who are aged fo ...

05.03.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.02.2025

ARS Pharmaceuticals Inc.

Automatic Shelf Registration Statement (Form S-3ASR)

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 81-1489190 (State ...

31.01.2025

ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Form 8 K

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy ® (epinephrine nasal spray) Preliminary fourth quarter neffy ® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an operating runway of at least three years Co ...

13.01.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES A ...

07.01.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

03.01.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

03.01.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

03.01.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

03.01.2025

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

03.01.2025

ARS Pharmaceuticals Inc. - news published 404 - readings 2.486

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Form 8-K)

ARS Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Material Event (Form 8-K)

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Automatic Shelf Registration Statement (Form S-3ASR)

ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Form 8 K

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

ARS Pharmaceuticals Inc.

Statement of Changes in Beneficial Ownership (Form 4)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member